Guest Editor(s)
-
- Prof. Shi-Yong Sun
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Website | E-mail
-
- Prof. Gen Sheng Wu
Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA.
Website | E-mail
-
- Prof. Yong Teng
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Website | E-mail
Special Issue Introduction
Apoptosis, pyroptosis, necroptosis, and autophagy are the most genetically well-defined cell death pathways intricately involved in physiological or pathological changes. Inherent or acquired drug resistance is a major obstacle to the success of cancer therapy. Although various mechanisms by which cancer cells become resistant to drugs in the intracellular and extracellular microenvironment have been well elucidated, how to circumvent this resistance to improve anticancer efficacy remains to be defined. Growing evidence has unraveled that cell death occurring in multiple forms is crucial in response to therapeutic stresses, contributing to the efficacy of anticancer drugs and drug resistance. Thus, establishing more effective and safe combinatorial therapeutic strategies by activating cell death-mediated mechanisms will be necessary to circumvent drug resistance. With the advent of new information, technologies, and methodologies, it is time to delineate the significance and enigmatic mechanisms relevant to cell death in response to drug resistance. This scientific evidence and innovative ideas are essential in translating science into practice effectively. This Special Issue aims to increase our understanding of concepts and molecular mechanisms relevant to cell death involved in drug resistance and possibly identify optimal therapeutic combinations for overcoming drug resistance.Therefore, we kindly invite you to contribute to this Special Issue with original research articles or comprehensive reviews on all aspects of “Recent Advances of Cell Death and Drug Resistance”.
Submission Deadline
30 Jun 2023
Cancer Drug Resistance
